Orion Corporation is establishing a new research & development centre in Cambridge, UK during 2025 to accelerate its global growth strategy and the development of innovative medicines.
The new centre will focus on the development of new biological and large-molecule therapies, with biologics CMC capabilities and project leadership to support the Orion biologics research projects which are moving towards clinical phase.
Professor, M.D., Ph.D. Outi Vaarala, Executive Vice President of Innovative Medicines and Research & Development at Orion, said: “Biologics are the fastest growing segment in pharma, representing huge opportunities for new innovative treatments.
“Cambridge is home to Europe’s largest biomedical research hub, and establishing our own Biologics R&D Centre in the area gives us access to a pool of world-class scientific talent and opportunities for collaboration with high-profile universities. I am thrilled about this continued internationalization of Orion’s R&D to build the best expertise for the future.”
Orion’s R&D organization currently consists of approximately 400 employees, with major sites located in Espoo and Turku in Finland and smaller clinical development hubs in Nottingham, UK and New York City, USA.
To ensure an organizational design that optimally supports Orion’s biologics R&D in future, a statutory negotiation process will start in Finland, which will impact approximately 20 employees working in Orion’s Protein and Antibody Engineering and Characterization teams in Turku. Other employees working in Orion R&D are not impacted.
